When a clinical trial is “double-blind,” neither the participant nor the treating physician knows who is receiving the active treatment and who is receiving the placebo. This design choice is one of the most important tools for producing unbiased, trustworthy medical evidence.
Why Blinding Matters
The placebo effect is real and powerful. When people believe they are receiving treatment, they often report feeling better, even when the substance has no active ingredients. In some conditions, placebo response rates of 30–40% are common.
Physician bias affects outcomes. Even the most careful physician will unconsciously respond differently to patients they know are receiving active treatment, in how they assess symptoms and record observations. Blinding eliminates this bias.
Data integrity requires objectivity. Clinical trial data must be collected without the distorting influence of either party’s expectations.
How It Is Done
The trial sponsor prepares identical-looking treatments, active drug and placebo, that cannot be distinguished by appearance, taste, or smell. A pharmacist dispenses them according to a randomization code held securely until the study is complete.
What If There Is an Emergency?
Blinded trials always have an unblinding procedure for medical emergencies. If a participant has a serious adverse event, the treating physician can immediately access the code for that individual without compromising the rest of the study.
Single-Blind and Open-Label Studies
Not all trials are double-blind. Some are single-blind (only the participant is blinded). Others are open-label, everyone knows what is being administered. Open-label studies are common in Phase I, in trials of treatments that cannot be adequately disguised, and in long-term extension studies.